Keywords: novartis, slovenian, subsidiary, lek, boosts, biopharma, activity

Novartis' Slovenian subsidiary Lek boosts biopharma activity

Article | 23 February 2004

Print This

Slovenian drugmaker Lek has launched a new recombinant technology unit - Port1 - as part of its increasing effort to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in